A new clinical trial is aiming to explore the potential of neuromodulation as a non-invasive approach to chronic pelvic pain. Initiated by the University Hospital, Grenoble, this randomized, double-blind study will assess three different approaches to direct current stimulation: trans-spinal stimulation, ganglionic stimulation, and placebo. Clinical teams and researchers in pain management and regulatory stakeholders should closely watch this development.
How is the study designed?
The study aims to evaluate the analgesic efficacy of direct current stimulation in chronic pelvic pain management. It is a double-blind, randomized clinical trial. Three groups of participants will receive either trans-spinal stimulation, ganglionic stimulation, or a placebo treatment. This design ensures that placebo effects can be accurately controlled for, while also enabling precise comparison between the two stimulation methods.
Currently, recruitment has not yet begun. Interested stakeholders can monitor updates through the official registration page on ClinicalTrials.gov (NCT07237165).
What are the treatment methods?
The primary intervention involves a non-invasive neuromodulation device that delivers direct current stimulation. Neuromodulation has gained attention in the medical device field for its ability to modulate nerve activity. The study will compare two specific stimulation techniques: trans-spinal stimulation targeting the spine and ganglionic stimulation focusing on nerve clusters. The placebo group will serve as a control for validating results.
Given the complexity of chronic pelvic pain, this study could significantly impact medical device innovations and treatment modalities. Safety, effectiveness, and clinical relevance will all be rigorously evaluated.
Why does this matter for regulatory teams?
For regulatory professionals, this trial may open discussions related to device classification, safety monitoring, and labeling within MDR Annex XIV frameworks. It will also contribute to the clinical evidence needed for neuromodulation devices targeting niche pain conditions. Familiarity with study outcomes can assist in proactive regulatory planning or submissions connected to similar device innovations.
The trial aligns with ongoing healthcare trends emphasizing non-invasive solutions and personalized treatments. Tracking updates is crucial for teams involved in marketing authorization applications or post-market surveillance programs.
FAQ
- What condition is the study targeting?
The trial focuses on chronic pelvic pain. - Who is leading the trial?
The University Hospital, Grenoble, is the sponsor of this investigation. - When will recruitment begin?
Recruitment has not yet started. Monitoring the trial’s ClinicalTrials.gov page is recommended for updates.
Conclusion
This new study marks an important opportunity to develop non-invasive neuromodulation for chronic pelvic pain management. The results could influence clinical strategies and regulatory frameworks. Both clinical and regulatory teams should stay tuned for updates as the trial progresses.
Disclaimer
This article is for informational purposes only and does not constitute legal or medical device regulatory advice. Readers should consult relevant guidelines or professionals for specific queries.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07237165?term=medical+device